NewAmsterdam Pharma Co N.V. (NAMS)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Ticker: NAMS
Exchange: Nasdaq
Sector: Healthcare
Industry: Biotechnology
Market cap: $2.26B
52-week range: $18.50 - $42.21

Valuation

Share price: $18.90 (close of Nov 6, 2026)
P/E (TTM): -11.25x
Price to book: 3.59x
Price to free cash flow: -15.01x
Enterprise value: $1.84B
Book value per share: $5.26

Price performance

Period	Change
1 day	+0.05%
5 days	-5.78%
1 month	-15.13%
3 months	-31.69%
6 months	-39.01%
Year to date	-46.12%
1 year	-48.99%
3 years	+83.14%
5 years	+92.27%
All time	+78.10%

Short interest

As of: Oct 15, 2026
Short % of float: 13.81%
Shares short: 14.11M
Days to cover: 10.64
Change since prior report: -25.91%
Source: FINRA consolidated short interest

Profitability and growth

Return on equity: -29.82%
Return on invested capital: -33.01%
Return on assets: -26.49%
Return on capital employed: -33.02%
Net margin: -905.74%
EBITDA margin: -1,000.78%
Revenue growth: -50.61%

Cash flow and balance sheet

Free cash flow yield (TTM): -6.66%
Current ratio: 11.76x
Net debt to EBITDA: 1.81x

Latest reported year

Period end: Dec 31, 2025
Fiscal year: 2025
Revenue: $22.50M
EBITDA: -$225.21M
Net income: -$203.82M
Earnings per share: $-1.72
Research and development: $141.83M
Shares outstanding: 118.42M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$22.50M	-	-$203.82M	-$1.72
2024-12-31	$45.56M	-	-$241.60M	-$2.56
2023-12-31	$14.09M	-	-$176.94M	-$2.15
2022-12-31	$102.69M	$96.78M	-$22.63M	-$1.19
2021-12-31	-	-	-$41.78M	-$3.81
2020-12-31	-	-	-$6.57M	-$0.71

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-12-31	-	-905.74%	-29.82%	-33.01%
2024-12-31	-	-530.25%	-31.89%	-23.26%
2023-12-31	-	-1,255.76%	-61.35%	-63.43%
2022-12-31	94.24%	-22.04%	-4.38%	-0.69%
2021-12-31	-	-	-74.10%	-61.83%

Cash and debt by year

Period end	Cash
2025-12-31	$490.00M
2024-12-31	$771.74M
2023-12-31	$340.45M
2022-12-31	$467.51M
2021-12-31	$60.13M
2020-12-31	$1.37M

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	-$148.03M	$59.42M
2024-12-31	-$159.24M	$33.62M
2023-12-31	-$141.24M	$24.57M
2022-12-31	$10.65M	$4.12M
2021-12-31	-$29.54M	$1.24M
2020-12-31	-$6.84M	-

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-11-04	Sep 2026	-$0.50
2026-08-05	Jun 2026	-$0.48
2026-05-07	Mar 2026	-$0.46
2026-02-18	Dec 2025	-$0.40
2025-11-05	Sep 2025	-$0.38
2025-08-06	Jun 2025	-$0.52
2025-05-08	Mar 2025	-$0.45
2025-02-26	Dec 2024	-$0.48

Filings and sources

Company website: newamsterdampharma.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades